“Sanofi appears to be taking advantage of the strong liquidity in biotech equity markets, and in REGN in particular, to accelerate the implementation of their strategy, and we do not expect them to sit on their new capital,” SVB Leerink analyst Geoffrey Porges wrote in a note on Tuesday.In another note Tuesday, Citi Research analyst Mohit Bansal wrote that the gene therapy company BioMarin Pharmaceutical (BMRN) was an unlikely target for Sanofi.